Holen Sie sich die Stockscreener-App
2.38
0.21%
-0.005
Vorhandelsmarkt:
2.30
-0.08
-3.36%
Schlusskurs vom Vortag:
$2.385
Offen:
$2.49
24-Stunden-Volumen:
10,968
Relative Volume:
0.01
Marktkapitalisierung:
$16.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.72M
KGV:
-0.9017
EPS:
-2.6394
Netto-Cashflow:
$-6.25M
1W Leistung:
+2.59%
1M Leistung:
-26.77%
6M Leistung:
-45.53%
1J Leistung:
-45.03%
1-Tages-Spanne:
$2.34
$2.49
1-Wochen-Bereich:
$2.2001
$2.55
52-Wochen-Spanne:
$1.55
$5.59
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Vergleichen Sie EDSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
2.38 | 16.64M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
H.C. Wainwright maintains $21 target on Edesa Biotech shares By Investing.com - Investing.com South Africa
Edesa Biotech completes US$15 million private placement - Fasken
Edesa Biotech files to sell 7.81M common shares for holders - MSN
Zacks Small Cap Boosts Earnings Estimates for Edesa Biotech - Defense World
EDSA: Raises 15 Million to Advance EB06 - Smartkarma
EDSA: Raises $15 Million to Advance EB06… - Yahoo Finance
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
Biotech Stocks To Keep An Eye On – February 13th - Defense World
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - GlobeNewswire
Edesa Biotech Advances Vitiligo Treatment Amidst Solid Financial Backing - TipRanks
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa Biotech Reports Q1 2025 Financial Results and Updates on EB06 Development for Vitiligo Treatment - Nasdaq
Edesa's Q1 Report Reveals Major Vitiligo Drug Progress: $15M Cash Injection Fuels FDA Push - StockTitan
US Penny Stocks To Watch In February 2025 - Simply Wall St
Edesa Biotech secures $15 million for clinical program By Investing.com - Investing.com Nigeria
Novartis to acquire Anthos Therapeutics for up to $3.1 billion - MSN
Edesa Biotech, Inc. announced that it has received $14.999992 million in funding from Velan Capital Investment Management LP and another investor - Marketscreener.com
H: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Edesa Biotech Inc (EDSA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Dow Jumps Over 100 Points; Deere Posts Upbeat Earnings - Benzinga
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Nasdaq Surges 150 Points; Cisco Earnings Top Views - Benzinga
Edesa Biotech shares jump on $15M private placement - MSN
Edesa Biotech (EDSA) Sees Sharp Stock Increase After Equity News - Stocks Telegraph
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy - MSN
US Stocks Edge Higher; Producer Prices Increase In January - Benzinga
Truist maintains Buy on Genmab stock, price target at $50 - MSN
Edesa Biotech announces $15 million private placement - MSN
Information Provided Pursuant to Early Warning Requirements with Respect to Par Nijhawan and Velan Capital - Financial Post
Edesa Biotech Announces $15.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Marketscreener.com
Edesa Biotech secures $15 million for clinical program - Investing.com India
Edesa Biotech Secures $15 Million in Private Placement to Advance Clinical Programs - TipRanks
Edesa Biotech announces $15M private placement priced at-the-market - TipRanks
Edesa Biotech Secures $15 Million for CXCL10 Antibody Program - TipRanks
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Major Funding Alert: Edesa's $15M Deal Fuels Breakthrough Vitiligo Drug Development - StockTitan
Dallas City Council approves planning deal for 2026 World Cup - MSN
Mawson Finland announces private placement for up to C$5M - MSN
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - MSN
Jabil acquires CDMO Pii to support drug development customers - MSN
Obesity drug developer Aardvark files for IPO - MSN
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… - Yahoo Finance
Edesa Biotech Announces $4.36 million Registered Direct Offering - ACCESS Newswire
Is Raytheon the Best Defense and Aerospace Stock to Own in 2025? - The Globe and Mail
Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update - Defense World
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):